ES2605946T3 - Imidazopiridazinas sustituidas - Google Patents

Imidazopiridazinas sustituidas Download PDF

Info

Publication number
ES2605946T3
ES2605946T3 ES13710986.4T ES13710986T ES2605946T3 ES 2605946 T3 ES2605946 T3 ES 2605946T3 ES 13710986 T ES13710986 T ES 13710986T ES 2605946 T3 ES2605946 T3 ES 2605946T3
Authority
ES
Spain
Prior art keywords
alkyl
group
halo
alkoxy
represent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13710986.4T
Other languages
English (en)
Spanish (es)
Inventor
Marcus Koppitz
Ulrich Klar
Antje Margret Wengner
Roland Neuhaus
Gerhard Siemeister
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Bayer Intellectual Property GmbH
Original Assignee
Bayer Pharma AG
Bayer Intellectual Property GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG, Bayer Intellectual Property GmbH filed Critical Bayer Pharma AG
Application granted granted Critical
Publication of ES2605946T3 publication Critical patent/ES2605946T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES13710986.4T 2012-03-14 2013-03-11 Imidazopiridazinas sustituidas Active ES2605946T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12159455 2012-03-14
EP12159455 2012-03-14
EP13154139 2013-02-06
EP13154139 2013-02-06
PCT/EP2013/054841 WO2013135612A1 (en) 2012-03-14 2013-03-11 Substituted imidazopyridazines

Publications (1)

Publication Number Publication Date
ES2605946T3 true ES2605946T3 (es) 2017-03-17

Family

ID=47913379

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13710986.4T Active ES2605946T3 (es) 2012-03-14 2013-03-11 Imidazopiridazinas sustituidas

Country Status (9)

Country Link
US (1) US9512126B2 (https=)
EP (1) EP2825540B1 (https=)
JP (1) JP6166289B2 (https=)
CN (1) CN104284896B (https=)
AR (1) AR090323A1 (https=)
CA (1) CA2867061A1 (https=)
ES (1) ES2605946T3 (https=)
UY (1) UY34677A (https=)
WO (1) WO2013135612A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104284896B (zh) 2012-03-14 2016-06-01 拜耳知识产权有限责任公司 取代的咪唑并哒嗪
RS56034B1 (sr) 2013-06-11 2017-09-29 Bayer Pharma AG Derivati prolekova supstituisanih triazolopiridina
CN105392484A (zh) * 2013-06-13 2016-03-09 拜耳制药股份公司 咪唑并哒嗪衍生物与有丝分裂试剂的联用药用于治疗癌症
FI3283642T3 (fi) 2015-04-17 2024-01-11 Crossfire Oncology Holding B V Prognostisia biomarkkereita ttk-inhibiittorikemoterapiaan
ES2839880T3 (es) 2015-07-07 2021-07-06 Janssen Vaccines & Prevention Bv Vacuna contra el VRS
GB201907616D0 (en) * 2019-05-29 2019-07-10 Galapagos Nv Novel compounds and pharmaceutical compositons thereof for the treatment of diseases

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
IL127566A0 (en) 1996-08-28 1999-10-28 Pfizer Substituted 6,5-hetero- bicyclic derivatives
DE69828607T2 (de) 1997-05-28 2006-01-05 Aventis Pharmaceuticals Inc. CHINOLIN- UND CHINOXALIN-VERBINDUNGEN DIE DEN VON BLUTPLÄTTCHEN ABSTAMMMENDEN WACHSTUMSFAKTOR UND/ODER PDGF- UND P56lck-TYROSIN-KINASE HEMMEN
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
JP2004346016A (ja) 2003-05-22 2004-12-09 Otsuka Chemical Co Ltd トリフルオロメチルキノキサリン化合物、その製造方法、及び有害生物防除剤
AU2004275694B2 (en) 2003-06-30 2008-03-06 Bizbiotech Co., Ltd. Compounds, compositions and methods
WO2006038116A2 (en) 2004-10-07 2006-04-13 Warner-Lambert Company Llc Triazolopyridine derivatives as antibacterial agents
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2007065010A2 (en) 2005-12-02 2007-06-07 Hif Bio, Inc. Anti-angiogenesis compounds
PT2029602E (pt) 2006-05-31 2010-07-08 Galapagos Nv Compostos de triazolopirazina uteis para o tratamento de doenãas degenerativas e inflamatërias
CN101528231A (zh) 2006-08-16 2009-09-09 埃克塞利希斯股份有限公司 在癌症的治疗中使用pi3k和mek调控剂
JP5336375B2 (ja) 2006-08-30 2013-11-06 セルゾーム リミテッド キナーゼ阻害剤としてのトリアゾール誘導体
WO2008133192A1 (ja) * 2007-04-19 2008-11-06 Takeda Pharmaceutical Company Limited 縮合イミダゾール化合物およびその用途
PE20090288A1 (es) 2007-05-10 2009-04-03 Smithkline Beecham Corp Derivados de quinoxalina como inhibidores de la pi3 quinasa
US8053574B2 (en) 2007-07-18 2011-11-08 Novartis Ag Organic compounds
WO2009021083A1 (en) 2007-08-09 2009-02-12 Smithkline Beecham Corporation Quinoxaline derivatives as pi3 kinase inhibitors
MX2010002115A (es) 2007-08-23 2010-06-01 Aztrazeneca Ab 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos .proliferativos.
CA2691448A1 (en) 2007-08-31 2009-03-05 Dominique Swinnen Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
MX2010005700A (es) 2007-11-27 2010-06-11 Cellzome Ltd Amino triazoles como inhibidores pi3k.
JP5599783B2 (ja) 2008-05-30 2014-10-01 アムジエン・インコーポレーテツド Pi3キナーゼの阻害薬
TWI491610B (zh) 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
WO2010092015A1 (en) 2009-02-10 2010-08-19 Cellzome Limited Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors
SG173610A1 (en) 2009-02-13 2011-09-29 Fovea Pharmaceuticals Sa [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors
CN102413831B (zh) 2009-04-29 2014-06-04 拜耳知识产权有限责任公司 取代的咪唑并喹喔啉
TW201107329A (en) * 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
CA2772790C (en) 2009-09-04 2017-06-27 Benjamin Bader Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343295A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
BR112012017310A2 (pt) 2010-01-15 2016-04-19 Janssen Pharmaceuticals Inc derivados de triazol substituídos como moduladores de gama secretase
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
ES2555261T3 (es) 2010-06-01 2015-12-30 Bayer Intellectual Property Gmbh Imidazopirazinas sustituidas
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
US9284317B2 (en) 2010-12-17 2016-03-15 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-a]pyrazines as MPS-1 inhibitors
ES2530802T3 (es) 2010-12-17 2015-03-06 Bayer Ip Gmbh Imidazopirazinas 6-tiosustituidas para uso como inhibidores de MPS-1 y TKK en el tratamiento de trastornos hiperproliferativos
HRP20150517T1 (hr) 2011-04-21 2015-06-19 Bayer Intellectual Property Gmbh Triazolopiridini
EP2734205B1 (en) * 2011-07-21 2018-03-21 Tolero Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors
CN104284896B (zh) 2012-03-14 2016-06-01 拜耳知识产权有限责任公司 取代的咪唑并哒嗪

Also Published As

Publication number Publication date
EP2825540A1 (en) 2015-01-21
CN104284896B (zh) 2016-06-01
CN104284896A (zh) 2015-01-14
WO2013135612A1 (en) 2013-09-19
CA2867061A1 (en) 2013-09-19
US20150104526A1 (en) 2015-04-16
AR090323A1 (es) 2014-11-05
JP6166289B2 (ja) 2017-07-19
HK1206022A1 (zh) 2015-12-31
UY34677A (es) 2013-10-31
JP2015513559A (ja) 2015-05-14
EP2825540B1 (en) 2016-09-14
US9512126B2 (en) 2016-12-06

Similar Documents

Publication Publication Date Title
ES2605946T3 (es) Imidazopiridazinas sustituidas
AR089143A1 (es) Triazolopiridinas sustituidas con actividad inhibidora de ttk
CR20170118A (es) Derivados espirodiamina como inhibidores de la aldosterona sintasa
ES2770058T3 (es) Compuestos y composiciones destinados a modular las actividades de quinasa de EGFR mutante
AR099177A1 (es) Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
AR101189A1 (es) Heterociclos nitrogenados antiproliferativos y sus métodos de uso
MX2019004578A (es) Oxisteroles y metodos de uso de los mismos.
AR103833A1 (es) Compuestos bicíclicos de sulfonamida cetona
MX2016011992A (es) Derivados de piperidina-diona.
AR094263A1 (es) Compuestos moduladores selectivos de proteinquinasas
PE20180483A1 (es) Oxiesteroles y metodos de uso de los mismos
EA201791873A1 (ru) Полиморф ингибиторов syk
CL2016002348A1 (es) Agonistas del receptor muscarínico
AR094300A1 (es) Derivados de quinolonas
AR085327A1 (es) Inhibidores del virus de la hepatitis c
MA39956A (fr) Analogues du benzomorphane et leur utilisation
MA40171A (fr) Dérivés d'azamophinan et leur utilisation
MX2018003590A (es) Compuestos y metodos para la inhibicion de jak.
CU20170007A7 (es) Compuestos de imidazopiridazina
AR094762A1 (es) Compuestos de hexahidropirano[3,4-d][1,3]tiazin-2-amina sustituida con heteroarilo
PE20160201A1 (es) Bencil-1h-pirazol[3,4-b]piridinas y su uso
AR111494A1 (es) Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer
MX2017011978A (es) Analogos deuterados de etifoxina, sus derivados y usos de estos.
CL2019000662A1 (es) Inhibidores de dopamina–b–hidroxilasa.
AR101528A1 (es) Inhibidores de cdk9 quinasa de pirrolo[2,3-b]piridina